Maribavir vs. Valganciclovir for CMV Prophylaxis in High-Risk Kidney Transplant Recipients

• Status: Recruiting
• Trial end date: 2025-11-30
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find out if there is a difference in how well the standard MUSC cytomegalovirus (CMV) prevention medicine works, compared to a different medicine, in preventing CMV infections in kidney transplant recipients who are at risk for this type of infection, while also assessing the tolerability of these two regimens. The two medication regimens being compared are Valganciclovir (FDA approved to prevent and treat CMV infection) vs Maribavir (FDA approved to treat CMV infection) plus Acyclovir (FDA approved to prevent HSV infection).

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical University of South Carolina
• Collaborator: Takeda
• Treatments: Maribavir; Valganciclovir

Criteria

Inclusion Criteria:

• Kidney transplant recipient at study institution

• =7 days of transplant

• Received at least one dose of rATG induction or patient is D+/R- CMV serostatus

Exclusion Criteria:

• Age <18 years at time of transplant

• Recipient of pancreas, liver, heart, lung transplant

• Recipient of investigational, non-FDA approved medication